Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
FDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drugPfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in Share XFDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drughttps://pharmaphorum.com/news/fda-sets-april-verdict-for-pfizers-underestimated-atopic-dermatitis-drug/
LEO eyeing 2021 US launch for eczema drug tralokinumabLEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the Share XLEO eyeing 2021 US launch for eczema drug tralokinumabhttps://pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/
Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUThe EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic Share XEyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUhttps://pharmaphorum.com/news/eyeing-dupixents-territory-leo-pharma-files-tralokinumab-in-eu/
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmaNICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in Share XNICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/nice-rejects-nhs-funding-sanofi-regenerons-dupixent-in-asthma/
Incyte gets much-needed boost as eczema cream trial hits targetUS biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream Share XIncyte gets much-needed boost as eczema cream trial hits targethttps://pharmaphorum.com/news/incyte-gets-much-needed-boost-as-eczema-cream-trial-hits-target/
Lilly swoops on Dermira to claim Dupixent rivalEli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a Share XLilly swoops on Dermira to claim Dupixent rivalhttps://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/
Novartis’ $100m bet on eczema drug fails as MOR106 development endsGalapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in Share XNovartis’ $100m bet on eczema drug fails as MOR106 development endshttps://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/
Pfizer’s Xeljanz follow-up abrocitinib gathers momentumPfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased Share XPfizer’s Xeljanz follow-up abrocitinib gathers momentumhttps://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/
